medigraphic.com

2019, Number 4

<< Back Next >>

Cir Cir 2019; 87 (4)

Ulcerative colitis: epidemiology, clinical features and associated factors with surgical treatment in a tertiary hospital in Mexico

de León-Rendón JL, Jiménez-Bobadilla B, López-Pérez RY, Gracida-Mancilla NI, Alarcón-Bernés L, Villanueva HJA

Language: Spanish
References: 49
Page: 450-458
PDF size: 183.33 Kb.


ABSTRACT

Background: An increase incidence of ulcerative colitis (UC) has been reported in Mexico. It is important to know the clinical features of patients with UC, their clinical course, need for surgical treatment and outcomes. Objective: To describe the demographic and clinical features of patients with UC, emphasizing the factors associated with the need for surgical treatment. Method: A retrospective, cross-sectional, analytical study was made which included 60 patients with diagnosis of UC confirmed by histopathology. The demographic, clinical and biochemical data of each patient will be collected. The severity was measured based on the Truelove and Witts scale, endoscopic Mayo score and Riley histological index. Results: Of the patients included, the proportion was equal between men and women. The mean age of presentation was 40.6 ± 13.3 years. The extent of the disease at the time of diagnosis was proctitis in the majority of patients (61.7%). Nineteen patients (31.8%) presented extraintestinal manifestations. 55% of the patients had as sole treatment 5-aminosalicylates. Fourteen patients (23.3%) required surgical treatment mainly due to lack of response to medical treatment. Conclusions: The clinical features of UC are useful to identify patients who may present a torpid evolution of the disease and who may require surgical treatment.


REFERENCES

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29.

  2. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am. 1995;24:475-507.

  3. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterology. 2001;120:622-35.

  4. Lakatos L, Lakatos P. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J. 2006;82:332-7.

  5. Yang SK, Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflammatory Bowel Dis 2001;7:260-70.

  6. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12 6102-8.

  7. Yamamoto-Furusho JK. Clinical epidemiology of ulcerative colitis in Mexico. A single hospital-based study in a 20-year period (1987-2006). J Clin Gastroenterol. 2009;43:221-4.

  8. Metcalf AM. Elective and emergent operative management of ulcerative colitis. Surg Clin North Am. 2007;87:633-41.

  9. Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum.2014;57:5-22.

  10. Hano García OM, Andrade Gomes S, Villa Jiménez OM, González FL, Wood RL. Characterization of patients with ulcerative colitis treated at tertiary center. Revista Cubana de Medicina. 2016;55:46-58.

  11. Loftus CG, Loftus Jr EV, Harmsen WS, Sandborn WJ. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007; 13:254-61.

  12. Thukkani N, Sonnemberg A. Epidemiologic characteristics of patients with inflammatory bowel disease undergoing colonoscopy. Inflamm Bowel Dis. 2011;17:1333-7.

  13. Molodecky NA, Panaccione R, Ghosh S, Barkema HW, Kaplan G, Environmental determinants of IBD. Clinical review. Inflamm Bowel Dis. 2011; 17:1992-8.

  14. Yamamoto-Furusho JK, Rodríguez-Bores L, Granados J. HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis. Colorectal Dis. 2010;(12):1231-5.

  15. Yamamoto-Furusho JK, De-León-Rendón JL, de la Torre MG, Alvarez- León E, Vargas-Alarcón G. Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis. Immunol Lett. 2013;149:50-3.

  16. Yamamoto-Furusho JK, De-León-Rendón JL, Alvarez-León E, et al. Association of the interleukin 15 (IL-15) gene polymorphisms with the risk of developing ulcerative colitis in Mexican individuals. Mol Biol Rep. 2014;41:2171-6.

  17. Bosques-Padilla FJ, Sandoval-García ER, Martínez-Vázquez MA, Garza- González E, Maldonado-Garza HJ. Epidemiología y características clínicas de la colitis ulcerosa crónica idiopática en el noreste de México. Rev Gastroenterol Mex. 2011;76:34-8.

  18. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140:1785-94.

  19. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27:1266-80.

  20. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841-54.

  21. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004;18:481-96.

  22. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006; 130:1941-9.

  23. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53.

  24. Molinié F, Gower-Rousseau C, Yzet T, Merle V, Grandbastien B, Marti R, et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988-1999). Gut. 2004;53:843-8.

  25. Portela F, Magro F, Lago P, Cotter J, Cremers I, de Deus J, et al. Ulcerative colitis in a Southern European country: a national perspective. Inflamm Bowel Dis. 2010;16:822-9.

  26. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158-65.

  27. Souza MH, Troncon LE, Rodrigues CM, Viana CF, Onofre PH, Monteiro RA, et al. Trends in the occurrence (1980-1999) and clinical features of Crohn’s disease and ulcerative colitis in a university hospital in southeastern Brazil. Arq Gastroenterol. 2002;39:98-105.

  28. Jiang XL, Cui HF. An analysis of 10,218 ulcerative colitis cases in China. World J Gastroenterol. 2002;8:158-61.

  29. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol. 2005;20:1691-5.

  30. Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20:9458-67.

  31. Morales Polanco S, Waller González LA. Validación del índice de severidad endoscópico de colitis ulcerativa para la población mexicana. Endoscopia. 2016;28:2-8.

  32. Travis SPL, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987-95.

  33. Rogler G, Bernstein CN, Sood A, Goh KL, Yamamoto-Furusho JK, Abbas Z, et al. Role of biological therapy for inflammatory bowel disease in developing countries. Gut. 2012;61:706-12.

  34. Pithadia AB, Jain S. Treatment of inflammatory bowel disease. Pharmacological Reports India. 2011;63:629-42.

  35. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis. 2006;12:212-7.

  36. Yamamoto-Furusho JK, Gutiérrez-Grobe Y, López-Gómez JG, Bosques-Padilla F, Rocha-Ramírez JL. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Rev Gastroenterol Mex. 2018;83:144-67.

  37. Yamamoto-Furusho JK, Bosques-Padilla F, de-Paula J, Galiano MT, Ibáñez P, Juliao F, et al. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn’s and Colitis Organisation. Rev Gastroenterol Mex. 2017;82:46-84.

  38. Stawowczyk E, Kawalec P. A systematic review of the cost-effectiveness of biologics for ulcerative colitis. Pharmacoeconomics. 2018;36:419-34.

  39. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold Ø, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population based follow up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543-50.

  40. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990;31:239-43.

  41. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9:156-63.

  42. Shiga H, Takagi S, Inoue R, Kinouchi Y, Ohkubo T, Takahashi S, et al. What determines the later clinical course of patients who do not undergo colectomy at the first attack? A Japanese cohort study on ulcerative colitis. Digestion. 2010;81:104-12.

  43. Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013;19:1858-66.

  44. Cosnes J. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis. 2010;28:411-7.

  45. Cañas-Ventura A, Márquez L, Ricart E, Domènech E, Gisbert JP, García- Sanchez V, et al. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis. 2014;8:1287-93.

  46. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-40.

  47. Aldhous MC, Drummond HE, Anderson N, Baneshi MR, Smith LA, Arnott ID, et al. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol. 2007;102:589-97.

  48. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-15.

  49. Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: can endoscopic evaluation predict outcomes? World J Gastroenterol. 2016;22:9324-32.




2020     |     www.medigraphic.com